University of Iowa Health Care: Department of Dermatology
Welcome,         Profile    Billing    Logout  
 3 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wofsy, David
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis

Recruiting
2
74
US
VIB4920, Placebo for VIB4920
National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Nephritis
08/26
03/27
NCT03239470: Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus

Terminated
1
5
US
Cohort 1: 1.0 x 10^8 PolyTregs, Polyclonal Regulatory T Cells, autologous PolyTregs, CD4+CD127lo/negCD25+ PolyTregs, Cohort 2: 2.5x10^8 PolyTregs
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Pemphigus Foliaceus, Pemphigus Vulgaris
12/20
01/23
Fairley, Janet
FJORD, NCT04612790 / 2020-000287-32: A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.

Jan 2024 - Dec 2024: Data from FJORD trial in patients with bullous pemphigoid
Terminated
3
67
Europe, Japan, US, RoW
Benralizumab, Benralizumab, Benra, Fasenra, Placebo
AstraZeneca
Bullous Pemphigoid
10/23
10/23
NCT04422912: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Recruiting
1
55
US
DSG3-CAART or CABA-201
Cabaletta Bio
Pemphigus Vulgaris
01/29
01/29
McKillip, Julie
No trials found

Download Options